Earlier in October of 2025, Professor Colleen Aldous was invited to give the inaugural keynote presentation to the Jackie Stone Memorial Lecture series, which was organized and hosted by the South African Vaccine Injury Medical Legal Study Group (savims.org.za), in honor of our heroic doctor and friend, the late Dr. Jackie Stone. This is a very poignant presentation, with an interesting conclusion at the end, about Jackie, her brilliance, courage, and tenacity, and the science of her COVID-19 treatment protocol. I will follow up with further updates if other presentation recordings become publicly available from the event.
The references cited throughout the presentation, by order in which they are mentioned, are as follows:
1. S.S. Jeremiah, K. Miyakawa, T. Morita, Y. Yamaoka, and A. Ryo: “Potent antiviral effect of silver nanoparticles on SARS-CoV-2“, Biochemical and Biophysical Research Communications 533(1) (2020), 195-200
2. F. Pilaquinga and J. Morey and M. Torres and R. Seqqat and M.N. Pina: “Silver nanoparticles as a potential treatment against SARS-CoV-2: A review“, WIREs Nanomedicine and Nanobiotechnology 13(5) (2021), e1707
3. C.A. Guzzo, C.I. Furtek, A.G. Porras, C. Chen, R. Tipping, C.M. Clineschmidt, D.G. Sciberras, J.Y. Hsieh, K.C. Lasseter, “Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects“, Journal of Clinical Pharmacology 42(10) (2002), 1122-1133.
4. Leon Caly, Julian D.Druce, Mike G. Catton, David A. Jans, Kylie M. Wagstaff. “The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro“, Antiviral Research 178 (2020), 104787
5. A. Bryant, T.A. Lawrie, T. Dowswell, E.J. Fordham, S. Mitchell, S.R. Hill, T.C. Tham, “Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines“, American Journal of Therapeutics 28(4) (2021), e434-e460
6. M. Popp and S. Reis and S. Schieber and R.I. Hausinger and M. Stegemann and M.-I. Metzendorf and P. Kranke and P. Meybohm and N. Skoetz and S. Weibel, “Ivermectin for preventing and treating COVID-19”, Cochrane Database of Systematic reviews (6) (2022), CD015017
7. D.E. Scheim, P.I. Parry, D.J. Rabbolini, C. Aldous, M. Yagisawa, R. Clancy, T.J. Borody, W.E. Hoy, “Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses“, Viruses 16 (2024), 647.
8. J.C. Stone, P. Ndarukwa, D.E. Scheim, BM Dancis, J. Dancis, M.G.Gill, C. Aldous, “Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours“, Biologics. 2022 2(3) (2022), 196-210.
9. E. Gkioulekas, P.A. McCullough, C. Aldous: “Critical appraisal of multi-drug therapy in the ambulatory management of patients with COVID-19 and hypoxemia. Part I. Evidence supporting the strength of association”, The Japanese Journal of Antibiotics 78(1) (2025), 2-34
10. E. Gkioulekas, P.A. McCullough, C. Aldous: “Critical appraisal of multi-drug therapy in the ambulatory management of patients with COVID-19 and hypoxemia. Part II: Causal inference using the Bradford Hill criteria“, The Japanese Journal of Antibiotics 78(1) (2025), 35-68
11. C. Aldous, B.M. Dancis, J. Dancis, P.R. Oldfield, “Wheel Replacing Pyramid: Better Paradigm Representing Totality of Evidence-Based Medicine“, Annals of Global Health 90 (1) (2024), 17
